NP-12 (Synonyms: AUR-012, SNTSESFK(SNTSESF)FRVTQLAPKAQIKE-NH2) |
| Catalog No.GC36767 |
NP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. NP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353563-85-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NP-12 is a peptide antagonist of the PD-1 signaling pathway, which acts as an immunomodulatory agent for cancer therapy[1]. PD-1[1]
NP-12 displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions [1].NP-12 rescues the proliferation in the mouse splenocyte assay system, with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively[1].NP-12 is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively[1].
[1]. Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *